Clinical Trial Update: Avelumab for People With Recurrent Respiratory Papillomatosis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating avelumab for recurrent respiratory papillomatosis completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Juvenile Laryngeal Papilloma
• Laryngeal Papilloma Recurrent
• Respiratory Papillomatosis

Drugs mentioned

• Avelumab (avelumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Respiratory Papillomatosis, Juvenile Laryngeal Papilloma | Phase 2 | Status: COMPLETED | Results posted: 2019-05-14